Description
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Peptide Blend
Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin are synthetic peptides that, through different proposed biological pathways, are suggested to support the stimulation and release of growth hormone (GH).
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that is believed to promote endogenous GH secretion by interacting with GHRH receptors. It consists of 44 amino acids and closely resembles natural GHRH in structure. Several modifications have been introduced to increase its stability and resistance to enzymatic breakdown. For instance, a trans-3-hexenoic acid modification at the C-terminus and an acetyl group at the N-terminus are thought to improve its durability and biological activity. When binding to GHRH receptors in the hypothalamus and pituitary, Tesamorelin is proposed to trigger GH release from somatotroph cells.
CJC-1295 (Mod GRF 1-29), also referred to as CJC-1295 without DAC, is a modified synthetic fragment of the active GHRH sequence (GRF 1-29). It is engineered to resist enzymatic degradation and exhibit an extended half-life. This tetrasubstituted peptide is believed to bind GHRH receptors on pituitary cells, potentially enhancing GH secretion. Research suggests it may act as a strong GH secretagogue with potential implications for protein synthesis, metabolic activity, and muscle development.
Ipamorelin is a synthetic pentapeptide that selectively targets the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R1a), found in both the hypothalamus and pituitary gland. It is considered highly selective, with minimal interaction with other endocrine pathways, making it of interest in GH-related research.
Chemical Composition
Molecular Formulas
- Tesamorelin: C221H366N72O67S
- CJC-1295 (Mod GRF 1-29): C152H252N44O42
- Ipamorelin: C38H49N9O5
Molecular Weights
- Tesamorelin: 5136 g/mol
- CJC-1295 (Mod GRF 1-29): 3367.9 g/mol
- Ipamorelin: 711.8 g/mol
Sequences
- Tesamorelin: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
- CJC-1295 (Mod GRF 1-29): L-tyrosyl-D-alanyl-L-alpha-aspartyl-…-argininamide
- Ipamorelin: alpha-methyl-alanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide
Alternative Names
- CJC-1295: GRF 1-29 albumin conjugate, GHRH derivative
- Ipamorelin: Ipamorelin acetate
Research and Clinical Findings
Pituitary Effects and GH Release
These peptides are believed to influence the pituitary gland through distinct receptor systems, ultimately affecting GH secretion.
Tesamorelin and CJC-1295 (Mod GRF 1-29) are thought to act via GHRH receptor activation, potentially initiating intracellular signaling cascades. This interaction may stimulate adenylate cyclase activity, increasing cyclic AMP (cAMP) levels, which can activate protein kinase A (PKA). PKA is then proposed to phosphorylate downstream targets, contributing to GH synthesis and release from pituitary somatotrophs. GH may also indirectly promote IGF-1 production in the liver.
CJC-1295 contains amino acid substitutions that may improve receptor interaction and enzymatic resistance. These modifications are also believed to enable strong binding to plasma proteins such as albumin, extending its circulation time and prolonging biological activity.
Ipamorelin, in contrast, acts as a selective agonist of the ghrelin receptor (GHS-R1a). Its binding is associated with targeted GH release while largely sparing other endocrine hormones such as prolactin and ACTH. It is thought to activate intracellular signaling pathways including PLC, leading to IP3 and DAG formation, calcium release, and PKC activation, ultimately promoting GH exocytosis from pituitary cells.
GI Tract Activity
Ipamorelin is also associated with activity in the gastrointestinal system through ghrelin receptor binding. It is proposed to influence gut motility, enhance nutrient absorption, and support tissue repair processes in experimental models.
Some studies suggest it may affect body composition and fat levels. It has also been investigated for its effects on gastric emptying, where it appeared to accelerate gastric transit compared with placebo in certain models. Additional research indicates possible effects on smooth muscle contractility, potentially improving gastrointestinal function under certain conditions.
Combined Mechanisms and Synergy
The rationale for combining Tesamorelin, CJC-1295, and Ipamorelin is based on their complementary mechanisms of stimulating GH release through different receptor pathways. Together, they are hypothesized to produce a stronger overall effect on GH secretion than any single compound alone.
Some imaging-based studies suggest Tesamorelin may be associated with changes in muscle composition, including increased muscle density and reduced fat infiltration in specific muscle groups. However, these changes were not consistently linked to IGF-1 fluctuations.
CJC-1295 has been associated in research with increased GH, IGF-1, and related binding proteins, alongside modest increases in lean body mass in experimental settings.
Ipamorelin has shown potential effects on muscle and bone in animal studies, possibly through IGF-1-related pathways, including increases in muscle fiber size and strength in preclinical models.
Closing Note
This peptide combination is described as being intended strictly for research and laboratory use only and not for human consumption.
Reviews
There are no reviews yet.